TW201821080A - 用於治療發炎性疾病之化合物及其醫藥組合物 - Google Patents

用於治療發炎性疾病之化合物及其醫藥組合物 Download PDF

Info

Publication number
TW201821080A
TW201821080A TW106139074A TW106139074A TW201821080A TW 201821080 A TW201821080 A TW 201821080A TW 106139074 A TW106139074 A TW 106139074A TW 106139074 A TW106139074 A TW 106139074A TW 201821080 A TW201821080 A TW 201821080A
Authority
TW
Taiwan
Prior art keywords
compound
treatment
pharmaceutically acceptable
acceptable salt
biomarker
Prior art date
Application number
TW106139074A
Other languages
English (en)
Chinese (zh)
Inventor
尚塔爾 特雷瑟 塔塞
斐勒 哈里森
雷內 亞歷山大 蓋倫
約翰 沙傑特 桑帝
約翰 G 麥哈奇森
湯瑪斯 奧賴爾登
尼路法 莫薩費里安
奧托 迪內希 佩托
提摩西 R 沃特金斯
大衛 L 勾薩居
Original Assignee
比利時商葛萊伯格有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商葛萊伯格有限公司 filed Critical 比利時商葛萊伯格有限公司
Publication of TW201821080A publication Critical patent/TW201821080A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW106139074A 2016-11-10 2017-11-10 用於治療發炎性疾病之化合物及其醫藥組合物 TW201821080A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
??1618959.9 2016-11-10
GB201618962 2016-11-10
GB201618963 2016-11-10
??1618961.5 2016-11-10
??1618962.3 2016-11-10
GB201618959 2016-11-10
??1618960.7 2016-11-10
??1618963.1 2016-11-10
GB201618961 2016-11-10
GB201618964 2016-11-10
GB201618960 2016-11-10
??1618964.9 2016-11-10

Publications (1)

Publication Number Publication Date
TW201821080A true TW201821080A (zh) 2018-06-16

Family

ID=60388032

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106139074A TW201821080A (zh) 2016-11-10 2017-11-10 用於治療發炎性疾病之化合物及其醫藥組合物

Country Status (8)

Country Link
US (1) US20190314382A1 (cg-RX-API-DMAC7.html)
EP (1) EP3538103A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019534304A (cg-RX-API-DMAC7.html)
AU (1) AU2017358703A1 (cg-RX-API-DMAC7.html)
CA (1) CA3043396A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019117562A (cg-RX-API-DMAC7.html)
TW (1) TW201821080A (cg-RX-API-DMAC7.html)
WO (1) WO2018087202A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115282168A (zh) * 2022-08-30 2022-11-04 马应龙大健康有限公司 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019132654A1 (en) * 2017-12-27 2019-07-04 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020009566A1 (en) * 2018-07-04 2020-01-09 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
US11602536B2 (en) 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
JP7518900B2 (ja) * 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN119157881A (zh) * 2024-09-25 2024-12-20 Jje有限公司 Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111956A1 (en) 2003-07-03 2007-05-17 Japan Science And Technology Agency Remedy for sarcoidosis and method of treating the same
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
DK2830662T3 (da) * 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
MX368511B (es) 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.
EP3060234A1 (en) * 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SMT202300328T1 (it) 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari
KR20170134750A (ko) 2015-04-13 2017-12-06 갈라파고스 엔.브이. 염증 질환의 치료 방법
AU2016259023A1 (en) * 2015-05-07 2017-11-30 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115282168A (zh) * 2022-08-30 2022-11-04 马应龙大健康有限公司 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用
CN115282168B (zh) * 2022-08-30 2024-05-31 马应龙大健康有限公司 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用

Also Published As

Publication number Publication date
EP3538103A1 (en) 2019-09-18
JP2019534304A (ja) 2019-11-28
WO2018087202A1 (en) 2018-05-17
AU2017358703A1 (en) 2019-05-09
US20190314382A1 (en) 2019-10-17
RU2019117562A (ru) 2020-12-10
RU2019117562A3 (cg-RX-API-DMAC7.html) 2021-02-09
CA3043396A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
US11844801B2 (en) Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
US11993605B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20190314382A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
US11512092B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
US20220251101A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
JP7751362B2 (ja) 乾癬性関節炎の治療方法
TWI794885B (zh) 全身紅斑性狼瘡之治療
US20220251105A1 (en) Methods of treating a mk2-mediated disorder
US11993606B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
JP2019515889A (ja) (1s,4s)−4−(2−(((3s,4r)−3−フルオロテトラヒドロ−2h−ピラン−4−イル)アミノ)−8−((2,4,6−トリクロロフェニル)アミノ)−9h−プリン−9−イル)−1−メチルクロロヘキサン−1−カルボキサミドの固体形態及びその使用方法
KR20260070285A (ko) 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
US20210353648A1 (en) Grapiprant unit dosage forms
TWI899163B (zh) 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
JP2022502441A (ja) Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
US12570664B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof